Tengion says clinical trial for bladder cancer treatment making progress

File photo

Tengion says an ongoing trial of a product for bladder cancer treatment will expand to more patients and more trial centers.

Tengion says an ongoing Phase 1 trial of a product it hopes will revolutionize bladder cancer treatment will expand to more patients and more trial centers.

The Winston-Salem-based Tengion Inc.? ? Tengion Inc. Latest from The Business Journals Tengion moving forward on reverse stock splitBodyMedia raises M, takes aim at mobile healthNASDAQ warns Tengion it does not meet standards Follow this company (NASDAQ: TNGN) said that it recently successfully implanted the fifth patient in the trial of the Neo-Urinary Conduit, which uses a patient's own cells to regenerate native-like urinary tissue to allow urine to exit the body after the removal of the bladder. Current technology uses repurposed bowel tissue, which presents complications for the patient.

Tengion, which is working to commercialize the ground-breaking regenerative medicine techniques developed by Dr. Anthony Atala's lab at the Wake Forest Institute for Regenerative Medicine, said it has also received permission to go ahead with concurrent enrollment of two more patients in the trial and continue on a pace to meet its goal of having ten patients in the trial by the end of the year.

The trial is also expanding to include four additional centers: Memorial Sloan-Kettering Cancer Center Inc.? ? Memorial Sloan-Kettering Cancer Center Inc. Latest from The Business Journals Rare cancer surgery now performed in New MexicoMemphis medical device company MRI Interventions goes publicBeitler takes aim at cancer Follow this company in New York, Baylor Charles Sammons Cancer Center in Dallas, the University of Michigan? ? University of Michigan Latest from The Business Journals New York consumers more upbeat about economy New Yorkers? consumer confidence highest since 2007U.S. consumer confidence varies wildly in separate studies Follow this company in Ann Arbor, Mich., and a to-be-announced site in Boston. The trial is already active at the University of Chicago Medical Center and The Johns Hopkins Hospital? ? Johns Hopkins Hospital Latest from The Business Journals Johns Hopkins Medicine expanding D.C. footprintDoes your training regimen need healing? Make the roundsJohns Hopkins Medicine targets D.C. area?s affluent neighborhoods Follow this company in Baltimore.

Matt Evans covers biotech, entrepreneurship, higher education, financial services and furniture. Contact him at (336) 370-2916.

death race buffet rule carlos santana baa dodgers triple play samoyed kenny powers